Drug Profile
TD 1439
Alternative Names: TD-1439Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Theravance Biopharma
- Class Small molecules
- Mechanism of Action Neprilysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Kidney disorders
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In the elderly, In volunteers, In adults) in USA (PO, Capsule)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Kidney-disorders(In the elderly, In volunteers, In adults) in USA (PO, Capsule)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers, In adults) in USA (PO, Capsule)